Related Experiment Video
Updated: Sep 27, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
[Genetic tests in oncology practice with emphasis on the RET oncogene and VHL tumor suppressor gene]
Gorana Nesković1, Boban Stanojević, Ivan Palmar
1gorana@vin.bg.ac.yu
Abstract:
Molecular oncogenetics is the study of two distinct gene classes participating in the pathogenesis of malignant diseases: proto-oncogenes and tumour suppressors genes. Stepwise alterations in their structure are the basis of malignancy. Structural abnormalities range widely: gross genetic rearrangements including insertions, deletions, gene amplifications and single nucleotide deleotide deletions and substitutions. These gene alterations are determined by gene testing that increasingly are part of clinical diagnosis. Among many applications of oncogene testing is detection of hereditary forms of malignant disease with outstanding prophylactic and therapeutic importance. Along this line, gene testing provided for effective prevention of specific hereditary tumour types. Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene. These genes were characterized about a decade ago and their structure determined in detail. Numerous studies focus on expression of these genes in different tissues and the function of respective proteins. In extensive epidemiology the following facts are established: hereditary mutations in the RET gene in > 92% of cases with MEN 2 syndrome while in patients with von Hippel-Lindau syndrome hereditary mutations were detected in VHL gene in > 95% of cases. Such a high genotype--phenotype correlation forms the basis for clinical applications. Gene testing in oncology offers numerous advantages. If a patient with pheochromocytoma presents with hereditary mutation in the RET or VHL gene, family gene testing is recommended. Family member with hereditary gene mutation is indicative of the risk level of nearly 100% for MEN 2 or von Hippel-Lindau syndrome. In such cases surgery is warranted (e.g. in MEN 2 total thyroidectomy by the age of (6). Negative findings in this type of gene testing relive family members from enormous psychological tension and provide them with normal family planning. There are many reasons to believe that this type of gene testing is the foundation of diagnosis for the 3rd millennium. Namely, results of gene testing may provide basis for effective prevention: mutations causative for a disease may be detected, presymptomatically and prenatally; the analysis requires only couple of mL of blood, and mutational status is determined only once in a lifetime.
Insights
Gene testing for hereditary pheochromocytoma, specifically analyzing the RET and VHL genes, enables early detection and prevention of Multiple Endocrine Neoplasia type 2 and von Hippel-Lindau syndrome.
Area of Science:
- Molecular oncogenetics
- Cancer genetics
- Hereditary cancer syndromes
Background:
- Malignant diseases arise from alterations in proto-oncogenes and tumor suppressor genes.
- Genetic testing is crucial for diagnosing hereditary cancers and guiding prophylactic strategies.
- Pheochromocytoma can be linked to hereditary syndromes like MEN 2 and von Hippel-Lindau.
Purpose of the Study:
- To highlight the role of gene testing in identifying hereditary pheochromocytoma.
- To emphasize the clinical utility of RET and VHL gene mutational analysis.
- To underscore the benefits of genetic screening for affected families.
Main Methods:
- Mutational analysis of the RET gene for Multiple Endocrine Neoplasia type 2 (MEN 2).
- Mutational analysis of the VHL gene for von Hippel-Lindau syndrome.
- Epidemiological studies to establish genotype-phenotype correlations.
Main Results:
- Hereditary mutations in the RET gene are found in over 92% of MEN 2 cases.
- Hereditary mutations in the VHL gene are detected in over 95% of von Hippel-Lindau syndrome cases.
- High genotype-phenotype correlation supports clinical application of gene testing.
Conclusions:
- Gene testing for RET and VHL mutations offers significant prophylactic and therapeutic advantages for hereditary pheochromocytoma.
- Family-wide genetic screening can identify at-risk individuals, enabling timely surgical intervention and preventing psychological distress.
- Presymptomatic and prenatal detection of causative mutations through gene testing forms a foundation for 21st-century cancer diagnosis and prevention.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...